Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma Science's book value per share for the quarter that ended in Mar. 2026 was ₹337.15.
During the past 12 months, Strides Pharma Science's average Book Value Per Share Growth Rate was 21.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Strides Pharma Science was 41.10% per year. The lowest was -9.30% per year. And the median was 4.65% per year.
During the past 13 years, the highest P/B Ratio of Strides Pharma Science was 3.43. The lowest was 0.49. And the median was 1.10.
Warning Sign:
Strides Pharma Science Ltd stock PB Ratio (=3.21) is close to 10-year high of 3.43.
Strides Pharma Science (NSE:STAR) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Strides Pharma Science Book Value per Share Related Terms
Strides Pharma Science Book Value per Share Historical Data
* Premium members only.
The historical data trend for Strides Pharma Science's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:STAR vs ZTS, UTHR: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's PB Ratio distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Book Value per Share of ₹337.15 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's Book Value per Share too high?
Strides Pharma Science's current Book Value per Share is ₹337.15. Overall, Strides Pharma Science has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Book Value per Share compare to ZTS and UTHR?
Strides Pharma Science's Book Value per Share of ₹337.15 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Book Value per Share is ₹337.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹779.94, compared to a current price of ₹1,082.60 — trading 38.8% above its estimated fair value. The current Book Value per Share is ₹337.15. Strides Pharma Science's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Book Value per Share is ₹337.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,082.60 is trading 38.8% above its estimated GF Value™ of ₹779.94.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Book Value per Share: ₹337.15
GF Value™: ₹779.94 vs. price of ₹1,082.60 (38.8% above fair value)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
74GF Score
Get the complete analysis for NSE:STAR
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
